Multicenter Experience with Efgartigimod Alfa in the Treatment of Anti-Nmdar Encephalitis Compared with Ivig and Spa-Ia During Acute Attacks
Опубликована: Янв. 1, 2025
Язык: Английский
Comparative the Efficacy of Efgartigimod and Intravenous Immunoglobulin on Aqp-4 Igg Positive Nmosd During Acute Attacks
Опубликована: Янв. 1, 2025
Язык: Английский
Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks
Life Sciences,
Год журнала:
2025,
Номер
unknown, С. 123597 - 123597
Опубликована: Апрель 1, 2025
Язык: Английский
Understanding supply sustainability of plasma‐derived medicinal products: Drivers and consequences of shortages
Vox Sanguinis,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 26, 2025
Abstract
Plasma‐derived
medicinal
products
(PDMPs),
particularly
immunoglobulins
(Igs),
are
essential
treatments
for
numerous
diseases,
often
serving
as
the
primary
therapeutic
option
and
playing
a
critical
role
in
patient
care.
The
human
origin
of
these
products,
however,
can
lead
to
supply
constraints
due
lack
plasma
collection,
market
dynamics,
regulatory
challenges
manufacturing
complexities.
Many
nations
self‐sufficiency
rely
on
United
States,
which
supplies
approximately
70%
world's
plasma.
This
chain
is
vulnerable
disruptions,
such
those
caused
by
COVID‐19.
Additionally,
processing
timelines
lengthy—Ig
takes
7–12
months
compared
with
2–3
biologics.
Despite
global
Ig
market's
projected
growth
from
$13.36
billion
$24.98
between
2023
2032,
shortages
persist.
European
Medicines
Agency
anticipated
affect
14
countries
2024.
These
factors
have
significant
implications
patients,
growing
demand
likely
leading
forcing
prioritize
certain
indications
face
shortages.
Policy
interventions
may
be
needed
ensure
sustainable
use
treating
immune‐mediated
disorders
related
conditions.
Exploring
alternative
where
possible
could
also
mitigate
risk
maintain
access
life‐saving
therapies.
review
examines
sustainability
PDMPs,
focusing
drivers
consequences
shortages,
insufficient
vulnerability
impacts
patients.
A
scoping
literature
research
was
conducted
PubMed,
supplemented
internal
knowledge
targeted
web
searches.
Язык: Английский
The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention
International Immunopharmacology,
Год журнала:
2024,
Номер
138, С. 112583 - 112583
Опубликована: Июль 6, 2024
Язык: Английский
Intravenous immunglobulin as a therapy for autoimmune conditions
Autoimmunity Reviews,
Год журнала:
2024,
Номер
unknown, С. 103710 - 103710
Опубликована: Ноя. 1, 2024
Язык: Английский
Epilepsy and Myasthenia Gravis: A Case Series
Brain Sciences,
Год журнала:
2024,
Номер
14(9), С. 870 - 870
Опубликована: Авг. 28, 2024
The
association
between
epilepsy
and
myasthenia
gravis
has
rarely
been
reported,
when
it
only
in
a
small
case
series.
aim
of
the
present
study
was
to
report
frequency
describe
series
patients
with
epilepsy,
focusing
on
their
clinical
characteristics
searching
for
possible
physiopathological
mechanism.
A
retrospective,
observational,
adult
center
conducted
2022.
Patients
were
recruited
from
database
outpatient
clinic
Myasthenia
Gravis
Epilepsy
Unit
Neurology
Service,
Hospital
Universitari
de
Bellvitge.
Five
included.
cohort
5/469
(1.1%),
5/1432
(0.35%).
All
suffered
focal
mainly
temporo-central,
which
drug-resistant
3/5
gravis,
generalized
exacerbations
3/5.
Three
thymectomized
(anatomopathology:
thymic
hyperplasia).
Other
autoimmune
diseases
found
two
(40%).
onset
preceded
all
patients.
Both
considered
autoimmune-related
3/5,
related
genetic
predisposition
due
altered
innate
immune
system
1/5,
chance
or
treatment
1/5.
are
infrequently
associated.
In
patients,
precedes
most
cases.
some
cases,
an
etiology
coexists
other
conditions.
Язык: Английский
Adult-onset neuronal intranuclear inclusion disease presenting with acute encephalitis-like episode and without characteristic hyperintensities on MR-DWI: a case report
Neurological Sciences,
Год журнала:
2024,
Номер
unknown
Опубликована: Июнь 9, 2024
Язык: Английский
Corticosteroids are still first-line therapies for bullous pemphigoid, with biologics finding use in difficult-to-treat disease
Drugs & Therapy Perspectives,
Год журнала:
2024,
Номер
40(8), С. 310 - 314
Опубликована: Июль 5, 2024
Язык: Английский
First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report
Isabelle Kwiedor,
Martina Menacher,
Monika Ellßel
и другие.
Therapeutic Advances in Neurological Disorders,
Год журнала:
2024,
Номер
17
Опубликована: Янв. 1, 2024
In
acetylcholine
receptor
(AChR)
antibody-positive
generalized
myasthenia
gravis
(gMG),
neonatal
Fc-receptor
(FcRn)
inhibition
has
broadened
the
therapeutic
spectrum.
Myasthenic
crisis
(MC),
heralded
by
an
impending
myasthenic
(iMC),
is
a
critical
condition
requiring
treatments
with
rapid
onset
and
sustained
efficacy.
Currently
used
for
iMC,
including
intravenous
immunoglobulins
plasma
exchange/immunoadsorption,
have
limitations,
such
as
delayed
of
action
potential
side
effects.
So
far,
there
limited
data
on
use
FcRn
inhibitors
in
management
or
manifest
MC
(mMC).
Here,
we
present
case
AChR
gMG
where
subcutaneous
administration
inhibitor
efgartigimod
resulted
clinical
remission.
Within
24
h
administration,
patient
exhibited
significant
improvement
respiratory
bulbar
muscle
function,
preventing
progression
to
need
mechanical
ventilation.
This
response
was
accompanied
marked
reduction
antibody
level
89.8%
within
4
weeks.
supports
fast-acting
effective
treatment
option
managing
offering
alternative
existing
therapies.
Язык: Английский